Biotechnology Startups funded by Y Combinator (YC) 2026

November 2026

Browse 22 of the top Biotechnology startups funded by Y Combinator.

We also have a Startup Directory where you can search through over 5,000 companies.

  • BioDelivera
    BioDelivera
    Y Combinator LogoF2026
    Active • 2 employees • San Francisco
    BioDelivera has developed proprietary GCV™, a drug delivery platform designed to travel through the body and selectively target diseased cells while sparing healthy ones. GCVs can carry genetic medicines, DNA, RNA, small molecules, or combinations of these at the same time. BioDelivera has demonstrated efficacy in tumors, muscle, and brain and is expanding to additional tissues. The company’s mission is to enable cures for every patient, across every disease.
    drug-delivery
    gene-therapy
    ai
    therapeutics
    biotechnology
  • Canos
    Canos
    Y Combinator LogoF2026
    Active0 • Oxford, UK
    Canos is bringing a human-grade liquid biopsy platform for dogs, starting with a single blood draw. We sequence cell-free DNA to perform multi-modal analysis of fragmentation, copy number variation, native methylation (5mC and 5hmC) and more to detect cancer signals. Owners bank a healthy baseline for their dog and track changes every year. Dogs already diagnosed get personalized monitoring through treatment. We partner with mobile vets and vet clinics to serve SF and NYC. Our mission is to make pet cancer curable through early detection and monitoring.
    anti-aging
    diagnostics
    biotechnology
  • Nitroduck
    Nitroduck
    Y Combinator LogoF2026
    Active • 3 employees • Brno, Czechia
    We make gene editing easy for all crops. To make pesticides obsolete across vegetables and fruits, enabling coffee to withstand heat waves, making almonds independent of pollinators, pistachios independent of winter chill, and much more. To let breeders create novel, consumer-facing crop varieties like pink pineapples, seedless cherries, and non-browning avocados.
    crispr
    sustainable-agriculture
    biotechnology
  • Lux Foods
    Lux Foods
    Y Combinator LogoF2026
    Active • 4 employees • San Francisco
    Lux Foods engineers ultra-compact plants that produce mostly fruit, then grows them on sugar with 90% less light. We design the biology and hardware together to make robotic farming easier. Starting with cherry tomatoes, we’re building year-round production of flavorful, nutritious, pesticide-free fruit near the people who eat it. Our tomatoes have been grown on the International Space Station, and now we're taking this technology to Earth.
    agriculture
    manufacturing
    cellular-agriculture
    robotics
    biotechnology
  • Primordiant
    Primordiant
    Y Combinator LogoF2026
    Active • 3 employees • San Francisco
    Every instance of intelligence occurring in nature is embodied. Scientific intelligence is no different. We are building general-purpose robotic experimentalists: systems that unite scientific reasoning and physical action to iterate toward discovery by observing, hypothesizing and experimenting.
    biotechnology
    energy
    robotics
    advanced-materials
    ai
  • TareBio
    TareBio
    Y Combinator LogoS2026
    Active • 1 employees • San Francisco
    Our platform develops personalized or population-level vaccines for any disease in weeks by changing only one input: the immune imprint. Instead of trying to predict which antigens might work, we read out immune cells already fighting the disease in the body and reverse-engineer antigens that activate them. We've already run our platform end-to-end and created a vaccine that cured cancer in mice.
    vaccines
    synthetic-biology
    biotechnology
  • Scoop
    Scoop
    Y Combinator LogoF2025
    Active • 2 employees • San Francisco
    We’re building AI agents that speed up drug trials by automating the manual consolidation and document prep required for every IND submission. Today, biotechs spend months stitching together reports from contractors and internal teams just to file and get to their first-in-human trial.
    biotech
    biotechnology
    compliance
    b2b
    ai
  • Paceline Bio
    Paceline Bio
    Y Combinator LogoF2025
    Active • 3 employees • Boulder, CO, USA
    Paceline Bio runs the research and clinical ops layer behind biotech and pharma company who want to move fast, starting with biospecimen collection, logistics, and storage. We're built to get you from scope to signature in just one day so you can accelerate your programs.
    biotech
    ai-powered-drug-discovery
    biotechnology
    drug-discovery
  • Uncommon Therapeutics
    Uncommon Therapeutics
    Y Combinator LogoW2025
    Active • 2 employees • San Francisco
    Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.
    gene-therapy
    biotechnology
    crispr
  • Evolvere BioSciences
    Evolvere BioSciences
    Y Combinator LogoS2024
    Active • 3 employees • Oxford, UK
    🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.
    ai-powered-drug-discovery
    biotech
    biotechnology
    therapeutics
    ai
  • Sensible Biotechnologies
    Sensible Biotechnologies
    Y Combinator LogoS2021
    Active • 55 employees • Oxford, UK
    The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
    synthetic-biology
    biotech
    manufacturing
    biotechnology
    therapeutics
  • Terraferma
    Terraferma
    Y Combinator LogoS2022
    Active • 6 employees • San Francisco
    Terraferma's high-titer platform bridges the gap between computational protein design and commercial production, combining AI/ML-guided strain engineering with ultra-high-throughput genetic screens to make more proteins faster, at lower economic and environmental cost.
    synthetic-biology
    biotechnology
    machine-learning
    automation
    manufacturing
  • Eugit Therapeutics
    Eugit Therapeutics
    Y Combinator LogoS2022
    Active • 2 employees • San Francisco
    Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
    therapeutics
    cell-therapy
    biotechnology
    oncology
    synthetic-biology
  • Alixia
    Alixia
    Y Combinator LogoW2022
    Active • 2 employees • San Francisco
    Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
    drug-discovery
    oncology
    therapeutics
    biotech
    biotechnology
  • SFA Therapeutics
    SFA Therapeutics
    Y Combinator LogoS2021
    Active • 4 employees • Philadelphia, PA, USA
    SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.
    ai-powered-drug-discovery
    biotech
    biotechnology
    health-&-wellness
    anti-aging
  • Volta Labs, Inc.
    Volta Labs, Inc.
    Y Combinator LogoW2019
    Active • 50 employees • Boston
    Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.
    hardware
    hard-tech
    biotechnology
    genomics
    robotics
  • UrbanKisaan
    UrbanKisaan
    Y Combinator LogoW2020
    Active • 53 employees • Hyderabad, Telangana, India
    UrbanKisaan is an AI-for-plant-biology company. We build foundation models and the physical infrastructure that trains them. Shipping a single new seed variety takes about ten+ years. Two on germplasm, three on crosses and selection, three or four on field trials, one on regulatory. Inside that decade, prediction and experiment never properly meet. DNA is abundant, phenotype data is scarce and unpaired, and the cycle never trains itself. We closed that loop. Three foundation models cover the upstream science. Aadi is a 48-layer transformer trained from scratch on the public and proprietary corpus of plant genomes; it reads plant DNA and ranks variants before any wet-lab spend. Jeeva is the genotype-to-phenotype model that turns a seed and a target environment into yield, flowering, maturity, and height with confidence intervals plus per-locus attribution. Akash is the geospatial backbone - it maps every pixel of every field to crop class and growing condition. Two pieces of physical infrastructure close the downstream half. GeneRush is a controlled-environment chamber engineered for speed: extended photoperiod, optimized temperature, integrated phenomics. Wheat reaches anthesis in 38 days. Breeding programs run 4–6 generations a year instead of 1–2. GrowRush takes that same chamber to commercial production scale, where every harvest is also a labelled phenotype training pair flowing back to Jeeva. The unit is paid for by what it grows; the science works because the unit is identical to the chamber the AI was trained on. Every cycle produces proprietary genotype-to-phenotype data the next generation of models needs. The ten-year breeding cycle compresses toward three. We are already commercial
    agriculture
    biotech
    sustainable-agriculture
    biotechnology
    ai
  • Mytos
    Mytos
    Y Combinator LogoS2018
    Active • 26 employees • London
    Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks. Last year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global capacity to produce these cells, and treat millions of patients. But today these Regenerative Medicines are produced by hand, meaning they’re too expensive and don’t scale. Mytos has fully automated production of these cells, making it scalable. We have our first manufacturing deal - neurons for treating Parkinson’s - and we’re in conversations with majority of the other top players.
    biotech
    hardware
    iot
    biotechnology
    automation
  • Solugen
    Solugen
    Y Combinator LogoW2017
    Active • 200 employees • Houston, TX, USA
    Solugen is decarbonizing the chemistry of everyday life with enzymes and innovative metal catalysts. Our new to the world Bioforge platform technology can produce high value chemical goods that are biobased and carbon negative, at cost on par with current technologies. We are making sustainable chemistry accessible to all living things, to ensure a prosperous world exists for generations.
    biotechnology
    climatetech
    industrial
    manufacturing
    climate
  • Lygos
    Y Combinator LogoW2016
    Active • 55 employees • San Francisco
    Performance materials company that used proprietary biology and chemistry to develop sustainable, high-performance ingredients and polymers. The company raised more than $200 million, scaled manufacturing, and commercialized products across agriculture, cleaning, personal care, and other specialty-materials markets. Lygos ultimately concluded through two strategic sales (DOD-funded organization, BioMADE and other strategic acquirers).
    biotechnology
    synthetic-biology
    climate
  • Nexa Labs
    Nexa Labs
    Y Combinator LogoS2025
    Acquired • 3 employees • San Francisco
    Nexa is developing the solution for cattle monitoring, leveraging implantable microchips that collect more comprehensive biometrics than anything else on the market. Our accompanying AI-driven animal health engine empowers farmers with early disease detection, reproductive insights, GPS tracking, and more. We're saving farmers time and money while collecting the world's largest cattle health dataset. We believe that cattle farming should be a science, not an art - this will secure the world's food supply and increase economic output that billions of people depend on.
    medical-devices
    agriculture
    livestock-health
    biotechnology
    ai